Clinical TrialsRisks such as slower-than-anticipated trial enrollment and negative efficacy data could impact the stock negatively.
Company RisksKey risks to the stock include negative clinical updates, financing risk, competitive pressure, and potential conflicts of interest due to business relationships.
Drug TolerabilityConcerns about the overall tolerability of the amivantamab combination due to a high rate of Grade 3+ adverse events were noted in the Phase 3 PAPILLON study.